Minutes of the 19th Institutional Review Board Meeting in FY2019 (Expedited review)

Date: Monday, March 2, 2020, 13:30 to 16:40

Place: Auditorium (Hiroshima) and the 3rd conference room (Nagasaki)

Participants:
IRB co-chairpersons: Dr. Kodama and Ms. Shinohara
IRB members: Dr. Yamada, Dr. Satoh, Dr. Sugiyama, Dr. Hida, Ms. Dodo, Ms. Ogawa, and Mr. Fuchi

Review of human genome/gene analysis research

	Department	Title of study	Review result	Summary minutes
1	Clinical Studies	Revision to RP6-15 "Epidemiological study of health effects in Fukushima emergency workers (Abbreviation: NEW Study)" (Kitamura *et al.*)	Approved	• The RP should state, "Transfer procedures are indicated in the attachment." and the appendix should be made into an attachment. • A Chinese character for "guaranteed" opt-out in the RP should be revised. • The information disclosure form must be amended to show that it guarantees an opt-out for the transfer. • The principal investigator and the appropriate contact person should be listed in the information disclosure form.

*The RP was approved by confirming that the aforementioned revisions were duly made.

Review of research involving human subjects

	Department	Title of study	Review result	Summary minutes
1	Epidemiology	Revision to the attachment to RP18-61 "Tumor registry study in Hiroshima and Nagasaki" and RP29-60 "Detection of leukemia and related disorders"	Approved	• The year used for the title of the RP included in the information disclosure form (Form 1-5-1) on page 10 should be changed from 2015 to 2017. • "Study participants of the clinical health study on the children of A-bomb survivors" should be added to the title of the RP on the information disclosure form (Form 1-5-2) and items 1 to 3 in the *objective and method of using samples/information* column should be consistent with the description in the information disclosure form (Form 1-5-1). • Add a column to describe the name of the proxy and the relationship with the person in question in the "Refusal to provide information in the national cancer registry" document. • Describe the selection policy of the proxy in the attachment. • Describe in more detail how personal information is handled in the Epidemiologic Analysis Laboratory in the attachment.

*The RP was approved by confirming that the aforementioned revisions were duly made.